KPAX002-1: Parkinson's Disease

Phase 2 ready. K-PAX is ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for the non-motor symptoms of Parkinson's disease. These symptoms include fatigue and excessive daytime sleepiness and represent a key unmet need in the treatment of this condition. A protocol synopsis of our phase 2 trial is available upon request.

KPAX002-2: Alzheimer's Disease

Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for the decreased alertness and cognitive symptoms of Alzheimer's disease. A protocol synopsis of our phase 2 trial is available upon request.

KPAX002-3:  Myalgic Encephalomyelitis/CFS 

Phase 3 ready. We have successfully completed phase 1 and phase 2 trials in patients with ME/CFS and are now ready to implement our pivotal phase 3 trial. The FDA has issued a draft guidance to industry and is on record as being highly motivated to approve a first treatment for this disease. KPAX002 is the leading candidate ready to take advantage of this unique opportunity. KPAX002 possesses strong IP protection through 2032.

Questions regarding partnering opportunities can be directed to K-PAX Pharmaceuticals' Director of Operations, Anne Lahaderne at: This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling (415) 381-7655.